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ABSTRACT 
Objective: Primary studies and systematic reviews provide varied accuracy 
estimates for prediction of pre-eclampsia. We undertook a review of published 
systematic reviews to collate published evidence on the ability of available tests 
to predict pre-eclampsia, to identify high value avenues for future research and 
to minimise future research waste in this field.  
 
Methods: We searched Medline, Embase, DARE (Database of Abstracts of 
Reviews of Effectiveness) and Cochrane Library databases (from database 
inception to March 2017) and bibliographies for systematic reviews and meta-
analyses without language restrictions. We assessed the quality of the included 
reviews using the AMSTAR tool and a modified QUIPS tool. We evaluated the 
reviews‟ comprehensiveness of search, size, tests and outcomes evaluated, 
data synthesis methods and predictive ability estimates and risk of bias related 
to population studied, measurement of predictors and outcomes, study attrition 
and adjustment for confounding.  
 
Results: From 2444 citations, we included 126 reviews, reporting on over 90 
predictors and 52 prediction models. Around a third of all reviews (29.3%, 
37/126) investigated biochemical markers for predicting pre-eclampsia; 24.6% 
(31/126) investigated genetic associations with pre-eclampsia, 36.5% (46/126) 
reported on clinical characteristics; 3.2% (4/126) evaluated only ultrasound 
markers; and 4.8% (6/126) studied a combination of tests. Reviews included 
between two and 265 primary studies, including up to 25,356,688 women in the 
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largest review. Only half (67/126, 53.2%) assessed the quality of the included 
studies. There was a high risk of bias in many of the included reviews, 
particularly in relation to population representativeness and study attrition. Over 
80% (106/126, 84.1%) summarised the findings with meta-analysis. Thirty-four 
studies (32/126, 25.4%) lacked a formal statement on funding. The predictors 
with the best test performance were body mass index (BMI>35 specificity 92%, 
95% CI 89-95% and sensitivity 21%, 95% CI: 12-31%; BMI >25 specificity 73% 
, 95% CI: 64-83% and sensitivity 47% , 95%CI: 33-61%), first trimester uterine 
artery Doppler PI or RI >90th centile (specificity 93%, 95% CI: 90%-96%) and 
sensitivity 26% (23-31%)), PLGF (specificity 89% , 95% CI: 89-89% and 
sensitivity 65% , 95% CI: 63-67%) and PP13 (specificity 88% , 95% CI: 87-89% 
and sensitivity 37% , 95% CI: 33-41%). No single marker had a test 
performance suitable for routine clinical use. The models combining markers 
showed promise, but none of the identified models had undergone external 
validation. 
 
Conclusion: Our review of reviews has questioned the need for further 
aggregate meta-analysis in this area, given the large number of published 
reviews subject to the common limitations of primary predictive studies. 
Prospective, well-designed studies of predictive markers, preferably in 
randomised intervention studies, and combined through IPD (individual patient 
data) meta-analysis are needed to develop and validate new prediction models 
to facilitate the prediction of pre-eclampsia and minimise further research waste 
in this field.  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
 INTRODUCTION 
 
Pre-eclampsia remains a major contributor to maternal and perinatal mortality 
and morbidity. (1,2) Early treatment with aspirin reduces the risk of pre-
eclampsia;(3,4) so accurate screening tests for pre-eclampsia are a clinical 
priority. Currently, clinical assessment of the risk of pre-eclampsia is based 
mainly on maternal history(5) with limited predictive ability, (6–8), and is not 
applicable to nulliparous women. Numerous primary studies have evaluated the 
predictive ability of various tests including clinical characteristics, biomarkers, 
and ultrasound markers, individually or in combination, for predicting early, late, 
and any onset pre-eclampsia.  
 
Systematic reviews collate evidence and aim to provide meaningful summary 
estimates of the predictive ability of tests through meta-analysis. Despite the 
number of published studies of predictive factors and screening tests for pre-
eclampsia, no consensus has been reached; neither clinicians nor national or 
international guidelines have implemented screening tests in routine clinical 
practice. This could be because no tests have been identified with adequate 
performance, but can also be attributed to the variable quality of the reviews. 
Very few validate existing prediction models (9) or report on test performance in 
various combinations, for different thresholds and outcomes.  
 
There is a need to map and critically appraise the available evidence in this field 
to minimise research waste and prioritise robust investigation of high yield 
predictive factors and models. We undertook a review of systematic reviews to 
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systematically collate and critically evaluate the published systematic reviews 
on risk factors identified as predictors for pre-eclampsia and the reported ability 
of individual tests to predict pre-eclampsia.  
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METHODS 
Our review of reviews was based on a prospective protocol according to current 
recommendations (10–12) and reported as per the PRISMA guidelines(13). The 
study was registered with the PROSPERO database (CRD42015020386, 
http://www.crd.york.ac.uk/PROSPERO).  
 
Literature search  
We searched Medline, Embase and the Cochrane Library including The 
Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of 
Reviews of Effects (DARE), The Cochrane Central Register of Controlled Trials 
(CENTRAL), Health Technology Assessment Database (HTA) and NHS 
Economic Evaluation Database (NHS-EED) from inception to March 2017. We 
used combinations of the relevant medical subject heading (MeSH) terms, key 
words, and word variants for “pre-eclampsia”, “gestational hypertension”, 
“pregnancy-induced hypertension” and “review” (Supplementary Material). No 
language restrictions were imposed. Reference lists of relevant articles and 
reviews were hand searched to identify additional papers.  
 
Study selection and data extraction 
Two reviewers (RT, AK) reviewed all abstracts independently. Any 
discrepancies on the potential relevance of the papers were resolved by 
consensus. We obtained full text copies of reviews that met the inclusion 
criteria.  
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We included reviews that assessed clinical characteristics, biochemical or 
ultrasound based variables as predictors or predictive tests for pre-eclampsia. 
We included reviews evaluating predictors in the first, second or third trimester. 
Case reports, case series, individual observational or randomised studies, 
narrative reviews, rapid reviews, editorials and poster abstracts were excluded. 
Two reviewers (RT, AK) independently extracted relevant data. We obtained 
data on year of publication, number of databases searched, number of studies 
included, number of pregnancies/women included, screening tests evaluated 
and the performance of the tests or degree of association reported with the 
predictors evaluated.   
 
Definitions  
We accepted the authors‟ definition of pre-eclampsia and hypertensive 
disorders, and further collected data where it was reported discriminating 
between early onset pre-eclampsia (requiring delivery prior to 34 weeks‟ 
gestation), late onset (delivery after 34 weeks‟ gestation) or delivery at any time.  
 
Clinical characteristics included signs, symptoms, past medical and obstetric 
history and environmental exposures elicited through maternal history or 
physical examination by the booking clinician at the first antenatal visit. 
Biochemical tests included any measurement of molecules in biological fluids 
(eg serum and urine). Ultrasound tests included any characteristic identified on 
ultrasound examination of the pregnancy at any gestation.  
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We defined a predictor as a clinical characteristic, biochemical or ultrasound 
marker with the potential to predict the outcome of interest (pre-eclampsia). We 
defined a predictive model as a combination of predictors obtained through 
logistic regression analysis to discriminate between populations.  
 
We defined a review as systematic if they included an explicit method for 
searching the literature, searched two or more databases, and if they provided 
well defined inclusion and exclusion criteria for studies.  
 
Quality assessment of the included reviews 
The rigour of the systematic review and risk of bias in the review findings were 
assessed using the AMSTAR tool and a modified approach to the QUIPS tool 
by two independent reviewers (RT, YP) (14–16) (Supplementary File 2).  For the 
AMSTAR assessment we considered whether the reviewers undertook the 
following: 'a priori' study design, a comprehensive literature search, the status of 
publication (i.e. grey literature) used as an inclusion criterion, duplicate study 
selection and data extraction, provided details of the included and excluded 
studies, reported the characteristics of the included studies, assessed and 
documented the quality of the included studies, appropriately used the scientific 
quality of the studies in formulating conclusions, used appropriate methods to 
combine the findings of studies, assessed the likelihood of publication bias and 
reported any conflict of interest. We assessed the risk of bias reported in the 
included reviews according to the QUIPS domains that relate to the key 
methodological concerns of prognostic research. We considered whether the 
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reviewers had assessed the representativeness of the patient sample, the 
impact of study attrition, predictor and outcome measurement, important 
confounders and the quality of the statistical analysis in the primary studies. 
Where this information was reported we considered whether the authors had 
made an assessment of the degree of associated risk of bias. For the studies of 
genetic factors we applied the Venice criteria(17) to assess the epidemiological 
credibility of the association based on the amount of evidence, replication and 
protection from bias in each study. 
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RESULTS 
Review identification 
Of the 2444 citations identified, 126 systematic reviews were included in our 
review. Figure 1 provides details of the review identification and selection 
process. A list of excluded studies is provided in Supplementary Table 1.  
 
Quality Assessment using the AMSTAR tool 
Figure 2a provides the findings of the quality assessment of the included 
reviews using the AMSTAR tool. Less than a quarter of the included reviews 
followed a prospectively specified protocol (24/126, 19.1%). Most of the reviews 
did perform a comprehensive literature search (120/126, 95.2%) with the 
majority of reviewers searching more than 2 databases. (Figure 2a) The 
majority of reviews undertook duplicate study selection (111/126, 88.1%), 
provided the characteristics of the included studies (109/126, 86.5%), and 
assessed the likelihood of publication bias (80/126, 63.5%). However, only a 
quarter provided a list of the included and excluded studies (28/126, 22.2%). 
About half (71/126, 56.3%) of the reviews performed their literature search 
without language restriction. (Figure 2a)  
 
Just over half assessed the quality of the included studies (67/126, 53.2%), and 
only a third took into account the quality of the studies in formulating their 
conclusions (38/126, 30.2%). The most commonly used tools for quality 
assessment were QUADAS (17/126, 13.5%) and the Newcastle-Ottawa Scale 
(NOS) (31/126, 24.6%) although neither are designed for predictive research. 
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None of the reviews published since 2013 used the Quality In Prognosis 
Studies (QUIPS) tool described in that year that is designed for predictive factor 
study quality assessment.(16)  
 
Although only half of the reviews assessed the quality of the included studies, 
many of the primary studies were potentially methodologically biased. They 
were often retrospective or case-control in design and subject to bias. Examples 
include significant heterogeneity; failure of masking of those managing the 
pregnancy or the outcome assessors; nested case-control studies including 
only a subset of pre-eclampsia cases of the original cohort and failure of 
application of the screening test to all the eligible participants in cohort studies. 
Furthermore, the included primary studies had numerous limitations including 
poor reporting of summary statistics, variable cut-offs of continuous variables, 
variation in outcomes assessed and the adjustment factors used to calculate 
test performance.(18)  
 
Risk of bias in included reviews assessed using the modified QUIPS tool  
 
Figure 2b shows the findings of the assessment of included studies against the 
modified QUIPS tool. Only one study reported on all domains. Of the included 
reviews, 80/126 (63.5%) reported on participants and representativeness of the 
population and 56/80 (70%) reported a high or moderate risk of bias in this area 
in the primary studies. Study attrition was considered in 31/126 (24.6%) with 
20/31 (64.5%) reporting a high or moderate risk of bias. Measurement of 
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predictors was evaluated in 101/126 (80.2%) reviews, with 63 (62.4%) 
describing a high or moderate risk of bias. Measurement of the outcome was 
well reported, considered in 109/126 (86.5%) of reviews, but 67/109 (61.4%) 
found a high risk of bias, most commonly related to heterogeneity or lack of 
clarity in the definition of the outcomes in primary studies. Confounding was 
considered in 84/126 (66.7%) and the review authors reported that 59/84 
(70.2%) had a high or moderate risk of bias relating to insufficient or 
inappropriate adjustment for important covariables.  
 
Characteristics of the included reviews 
The included reviews reported on between 3 and 265 primary studies, with the 
majority including 10-50 primary studies and including up to 25,356,688 
pregnancies in the largest review(19). (Figure 3) Seventy-nine predictors were 
evaluated in the included reviews (Table 1). The majority of reviews (53.9%, 
68/126) investigated biochemical or genetic tests for predicting pre-eclampsia 
while 36.5% (46/126) related to clinical characteristics. Ultrasound markers 
were reported in only 3.2% (4/126) and a combination of tests in 4.8% (6/126) 
of reviews (Figure 3). We identified two previous broad systematic reviews of 
primary studies investigating all screening tests for pre-eclampsia (20,21) from 
2004 and 2008.  
 
The most commonly reported clinical characteristics included BMI (n=9 
reviews), age (n=2), parity (n=2), blood pressure (n=5) and 6 reviews reported 
on several clinical characteristics. For the biochemical markers, the following 
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were most commonly studied: PAPP-A (n=4), PlGF (n=5), sFlt-1 (n=3), PP13 
(n=4). Over 30 additional markers were reviewed. The ultrasound tests included 
uterine artery dopplers (n=8) and placental vascularisation indices (n=1). Only 
two reviews (22,23) summarised the findings with an individual participant data 
(IPD) meta-analysis. The details of the included reviews (19–144) and key 
findings are shown in Table 2. Table 2a describes reviews of maternal 
characteristics, 2b relates to reviews of ultrasound markers, 2c to reviews 
including biomarkers singly or in combination with other factors and 2d to the 
genetic association studies.  
 
The majority (67/126, 53.2%) of the included reviews reported odds ratio as a 
single measure of predictor association with pre-eclampsia rather than directly 
reporting predictive ability of the predictors investigated.  (Table 2). Only 31/126 
(24.6%) studies reported measures of predictive ability, with 19 reporting 
sensitivities and specificities, 6 area under the receiver operating curve (AUC) 
and 6 likelihood ratios (LR). 
 
Twenty-one studies declared no funding had been received, while 32 studies 
lacked a formal statement regarding funding of the studies. Of the remaining 
studies, 14 (19.2%) declared multiple funding sources. The majority of studies 
(51/73, 69.8%) declaring their funding sources had been sponsored by national 
or regional governmental bodies (e.g. National Institute for Health 
Research (NIHR), National Institutes of Health (NIH), Canadian Institutes of 
Health Research (CIHR), Health technology Assessment (HTA), National 
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Health and Medical Research Council (NHMRC)). Nearly one quarter (21.9%) 
were funded through academic institutions, 19.2% by charitable bodies, 4.1% 
received funding from industry and 9.5% by international bodies, chiefly the 
World Health Organisation.  
 
There was substantial variation in outcome reporting, including failure to report 
gestation at delivery and severity of pre-eclampsia. Despite the fact that there 
has been a transition from a severity-based to a temporal classification of pre-
eclampsia (145), only three reviews reported early-onset pre-eclampsia, probably 
because the outcome was infrequently reported in primary studies (Figure 2). 
Some studies combined pre-eclampsia with hypertensive disorders, which 
limited the comparisons between studies. Considerable heterogeneity was 
highlighted in many of the included reviews and precluded meta-analysis in 
15.1% (19/126) reviews.   
Key individual predictors for pre-eclampsia  
 
The included reviews reported on over 90 predictors for pre-eclampsia.  The 
findings of the included reviews are summarised in Table 2. For each predictor 
we applied the  Grades of Recommendation, Assessment, Development, and 
Evaluation (GRADE) approach to prognostic studies(146) to assess the quality of 
the evidence supporting the associations found. (Supplementary table 3). The 
most robustly associated clinical, ultrasound and biochemical predictors 
included BMI, blood pressure, uterine artery Doppler findings and PLGF, sFlt-1 
and AFP. (Supplementary Table 4)  
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Clinical characteristics  
Maternal BMI was analysed as a continuous, binary or categorical variable, and 
was consistently considered to be a weak predictor of pre-eclampsia with a 
number of studies demonstrating a biological gradient, with increasing BMI 
increasing the risk of pre-eclampsia (98, 106). Increased maternal blood pressure 
(BP), evaluated alone(19,132,136) or in combination with other predictors, (19, 61) in 
the first or second trimester, was also consistently associated with an increased 
risk of pre-eclampsia, but the measurement of blood pressure varied between 
studies.(16, 105, 108) In 2008 Cnossen et al compared the predictive ability of 
systolic and diastolic blood pressure (SBP and DBP) and mean arterial 
pressure (MAP) measured at booking and found that mean arterial pressure 
had a greater area under the curve (AUC 0.76, 95% CI 0.70-0.82) than either 
diastolic or systolic blood pressure for all pre-eclampsia.(132) 
 
Other clinical characteristics evaluated that demonstrated a consistent 
association were donor oocyte use in assisted reproduction, sleep disordered 
breathing, polycystic ovary syndrome, periodontal disease and maternal 
infections.  
 
Ultrasound markers  
First trimester uterine artery Doppler (UtAD) appears to have high specificity 
(92.1%, 95% CI: 88.6-94.6), but low sensitivity (47.8%, 95% CI: 39.0-56.8%) in 
predicting early onset pre-eclampsia.(25) The sensitivity of UtAD was even lower 
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for predicting any pre-eclampsia at only 26.4% (95% CI: 22.5-30.8%)(25). One 
review evaluated placental vascularisation indices (PVIs) measured at 3D 
ultrasound and found  that PVI measured in the first trimester were found to be 
predictive of later pre-eclampsia with the most sensitive measure being the 
vascular flow index (VFI).(144) The authors reported an AUC for the prediction of 
early pre-eclampsia by the vascular flow index of 0.89 (95% CI: 0.78-1.00) and 
for any pre-eclampsia of 0.77 (95% CI: 0.69-0.84). (144)     
 
Biochemical markers  
The biochemical screening markers were grouped according to their 
mechanism of action (Table 2). Of markers associated with angiogenesis, both 
PlGF and sFlt-1 were consistently associated with the risk of pre-eclampsia, 
with an odds ratio of 9.0 (95% CI 5.6–14.5) for PlGF tested before 30 weeks in 
one large study(49) and although another reported no significant association 
between first trimester PlGF and all pre-eclampsia OR 1.94 (95% CI 0.81 to 
4.67) there was an association between first trimester PlGF and early onset PE 
(OR 3.41 ((95% CI 1.61-7.24). (96) For sFlt-1 odds ratios from 1.3 (95% CI 1.02-
1.65) to 6.6 (3.1–13.7) were reported, with the association being stronger when 
tested later in pregnancy. (49,96) For a 5% false positive rate, PlGF and sFlt-1 
had sensitivities of 32% and 26%, respectively. (49) Soluble endoglin (sEng) and 
VEGF were not as consistently found to be associated although at least one 
study reported that sEng had a sensitivity of 18% to detect PE for a 5% false 
positive rate. (49) Of the markers routinely tested during aneuploidy screening in 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
the first trimester, alpha feto protein (AFP) had the highest specificity of 96% 
(95% CI 94 to 98%) with a specificity of only 9% (95% CI 5-16%). (20)  
 
A wide number of gene mutations were considered to be associated with the 
development of pre-eclampsia, but no single polymorphism was identified with a 
clinically useful predictive performance. (Table 2). The most frequently 
investigated genes were methylenetetrahydrofolate reductase (MTHFR) and 
endothelial nitric oxide synthase (eNOS), and a number of genes relating to 
elements of the renin-angiotensin-aldosterone system (RAAS) were 
investigated. The credibility of the association between the MTHFR C677T 
mutation and pre-eclampsia was generally weak and the association was not 
large. The credibility of association with mutations of the eNOS gene was 
moderate, but again this was not a large effect. These patterns do support an 
association between endothelial and RAAS function and pre-eclampsia, but are 
not at present useful for prediction of disease.  
 
Multivariable prediction models  
No screening marker, whether any of the clinical characteristics, ultrasound or 
biochemical markers, had both sensitivity and specificity greater than 90%.  
 
Six reviews opted for an approach using combinations of predictive markers 
(Table 2)(22,85,88,97,99,100) and reported results for 52 individually described 
models while one group reported on an additional 70 models in groups labelled 
as „simple‟ or „specialised‟ based on the inclusion of ultrasound and biochemical 
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tests. (99) Of these studies, only one reported calibration statistics for the model 
described (22) and one found that of the 14 primary model development papers 
assessed, only 6 reported model calibration. (99) The remaining prediction 
modelling papers did not describe calibration of the models presented or assess 
calibration statistics in the primary studies reviewed. The detection rates (DR) of 
single markers (ADAM12, beta-hCG, inhibin A, activin A, PP13, PlGF and 
PAPP-A) for early-onset pre-eclampsia ranged from 22% to 83% for a fixed 
false positive rate of 10%. (88) These figures improve to between 38% and 100% 
when a combination of more than two markers was used. (88) The best results 
(DR 100%, 95% CI 69-100%) were achieved with the combination of three 
biochemical markers (Inhibin A, PlGF, PAPP-A), uterine artery Doppler and 
maternal characteristics. (88) For early-onset pre-eclampsia, a model containing 
only BMI was signiﬁcantly improved by the addition of mean resistance index 
(RI) and bilateral notching, with the AUC increasing from 0.66 to 0.92 
(P<0.001). The addition of mean pulsatility index (PI) and bilateral notching 
improved the AUC from 0.62 to 0.95 (P<0.001). (22) The sensitivity for early-
onset pre-eclampsia using uterine artery Doppler PI, with mean arterial 
pressure was 83%, (85) but only 58.5% for late onset pre-eclampsia with the 
same markers. The improved performance of models containing Doppler or 
biomarkers is consistent with the finding of one study that adding ultrasound or 
biomarkers to models based on maternal characteristics alone led to a median 
gain of 18% in sensitivity.(99)  
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DISCUSSION 
Our review identified 126 systematic reviews on over 90 predictors for pre-
eclampsia, although only around a quarter directly reported predictive ability. No 
test was found to have sensitivity and specificity above 90%. A high sensitivity 
and specificity are necessary to make screening more cost effective than a 
„treat-all‟ policy in clinical practice.(20) BMI >34kg/m2, AFP and bilateral uterine 
artery Doppler notching were reported with specificity of >90% but with low 
sensitivities, rendering them unsuitable to safely categorise women as „low risk‟. 
(20) Individual predictors most correlated with pre-eclampsia were uterine artery 
Doppler indices and angiogenic biomarkers. (22,88,143) Prediction models 
combining maternal characteristics (particularly BP) with uterine artery Doppler 
and biomarkers were able to achieve sensitivity and specificity >80%. (22,85,100)  
 
Comparison with existing evidence   
Our search identified one prior „umbrella‟ review on this topic (147) and two broad 
systematic reviews of primary studies for prediction of pre-eclampsia from the 
HTA in 2008 (20) and the World Health Organisation (WHO) in 2004.(21) All three 
also identified BMI, uterine artery Doppler and AFP as high performing variables 
but were also limited by heterogeneity and inconsistent reporting in included 
primary studies.(20) A subsequently published review of systematic reviews of 
risk factors for pre-eclampsia, while not examining uterine artery Dopplers, also 
identified a number of maternal characteristics as important risk factors 
including obesity, primiparity and smoking status and additionally noted the 
strong association between assisted reproduction and pre-eclampsia that 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
should be considered in the development of new prediction tools.(148) Several of 
these studies reported evidence that infrequently studied predictors including 
kallikreinuria and fibronectin might offer high sensitivity in pre-eclampsia 
prediction and required further research. No new reviews including these 
predictors were identified in our search nearly ten years later although new 
variables, including cell free fetal DNA, can be added to the selection of 
variables that require further investigation. Previous reviews have also 
highlighted the need for development of multi-variable models. In this review we 
have identified over 50 models that have been reported in the last decade, but 
we also found none that had undergone external validation and could be 
recommended for routine practice.  
 
Strengths and weaknesses 
The strengths of this review include a thorough search strategy and critically 
evaluative approach. The analysis collates a wide variety of reviews 
representing the state of research in this field. The findings of the review are 
limited by the quality of included studies, compromised by limitations carried 
over from the primary studies and then the later conduct of the review analysis, 
especially where investigators did not address risks of bias particular to 
prediction research.  
 
Clinical and research implications  
Maternal characteristics at booking are currently used for screening by most 
guidelines. (5,149,150) An important characteristic, due to increasing prevalence, is 
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maternal obesity. (151,152) This review confirmed a plausible biological gradient 
associating maternal obesity with pre-eclampsia and observed that the inclusion 
of BMI improved the performance of several models.(22,88) It is likely that any 
clinically useful model would be improved by inclusion of a measurement of 
maternal obesity.  
 
In seeking to improve on screening by maternal characteristics, many 
biomarkers were investigated. The angiogenic markers are most promising, 
particularly PlGF and sFlt-1.(49,61,84,95,96) Of the placental proteins, PP13 and 
PAPP-A were most consistently associated. (41,61,95,96,101) Large prospective 
studies using biomarkers are expensive and most data exists for markers 
routinely obtained during fetal anomaly screening. There is evidence in smaller 
studies for markers like fibronectin,(20,73) cell free fetal DNA (31,62) and urinary 
kallikrein(20,21) that requires further investigation. 
 
This review further confirmed the screening performance of uterine artery 
Doppler in the first and second trimesters. Using a model combining systolic 
blood pressure, uterine artery PI and bilateral notching with BMI can achieve 
AUC 0.85 (95% CI: 0.67–1.00).(22) but this model is as yet still undergoing 
external validation, in the SPREE study comparing the National Institute for 
Health and Care Excellence (NICE) and Fetal Medicine Foundation (FMF) 
screening models.(153) 
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While in previous years the search has been for a single marker to predict pre-
eclampsia, recognition of the heterogeneity of the disease phenotype and 
complexity of prediction has led to consensus that the best approach to pre-
eclampsia screening is likely to be calculating individualised risk based on a 
combination of markers. (6) In this review we have identified key predictors that 
could be used in developing such a prediction model and propose a solution to 
address the problems of inconsistent reporting and heterogeneity that have 
consistently affected the ability of prior reviews to make recommendations on 
screening.(20,21,147) Since information on multiple predictors will be required, 
model development will optimally utilise individual level data which can facilitate 
analysis to identify the predictors that explain most of the variance of the full 
model. The aim of this approach, already established in cardiovascular 
prediction modelling,(154) is to develop a model well balanced between optimal 
performance and parsimony of included predictors leading to greatest ease of 
use in clinical practice.  
 
Using individual patient data meta analysis for model development (IPD-MA) 
could additionally address poor reporting and heterogeneity in primary studies. 
While resource intensive and still subject to publication bias, IPD-MA is 
becoming the gold standard for predictive meta-analysis. (155) The advantages 
of IPD-MA over conventional meta-analysis include use of all available data; 
flexibility to combine data uniformly; the use of original data allowing analysis of 
continuous variables and comparison between datasets. (156) Moreover, it 
permits comparison of multivariable prediction strategies and the possibility of 
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time-to-event analysis, particularly relevant to pre-eclampsia where gestation is 
inextricably linked to maternal and fetal outcomes. (157)  
 
Research priorities should include prospectively registered predictive studies of 
promising markers, with results for each marker alone and in combination with 
other tests and clear reporting of methods and timing of variable and outcome 
measurements. A particular focus should be high performance tests in the first 
trimester, when the benefits of intervention are greatest. IPD meta-analysis 
combining the most promising predictors can then be used to develop prediction 
models for external validation before introduction into clinical practice.  
 
Predictive variables by themselves do not improve outcome; the subsequent 
preventive interventions do. Since it is not self-evident that a treatment has a 
stable effect in women with different profiles, predictive markers should be 
evaluated in studies that evaluate the impact of predictive strategies. (158) The 
ideal predictor not only predicts pre-eclampsia, but also predicts treatment 
modification, i.e. whether a treatment improves the outcome in a particular 
category of patients.  
 
In order to conduct effective primary studies and analyses, consensus on 
outcomes is needed. Identification of a core outcome set for pre-eclampsia 
studies (159) is a key priority. Such an approach will enable us to move beyond 
repeating small, low quality prognostic factor studies to investigating the clinical 
impact of prediction model use in clinical practice.  
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Figure Legends 
 
Figure 1 Flow chart illustrating identification of studies included in this 
systematic review.  *some studies reported on markers in more than one 
category 
 
Figure 2a - AMSTAR assessment of included studies 
Figure 2b - QUIPS assessment of included studies 
 
Figure 3. Summary of characteristics of included studies 
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Table 1. Screening markers for pre-eclampsia investigated in systematic reviews  
Maternal characteristics 
 Age 
 Parity 
 Body mass index 
 Previous pre-eclampsia 
 Family history of pre-eclampsia 
 Multiple pregnancy 
 Pre-existing medical conditions (such as diabetes, antiphospholipid syndrome) 
 Interval between pregnancies 
 Common occupational exposures (prolonged working hours, shift work, lifting, 
standing and heavy physical workload) 
 Infection (bacterial/viral/other) 
 Periodontal disease 
 Mental stress 
 Polycystic ovary syndrome 
 ABO blood group status 
 Ambient air pollution 
 Coeliac disease 
 Dietary factors (energy, nutrients, foods or overall dietary patterns, alone or in 
combination with dietary supplements) 
 Cigarette smoking 
 Donor insemination/donor oocyte use  
 Physical activity 
 Intra-uterine device (IUD) use  
 Meteorological conditions  
 Obstructive sleep apnoea  
 Chorionic villus sampling 
 Past obstetric history (previous pre-eclampsia, stillbirth, growth restriction or 
abruption)  
 Flow mediated dilatation (FMD) 
 Blood pressure 
Ultrasound markers 
 Uterine artery Doppler 
 Placental vascularisation indices  
Biochemical markers 
Angiogenic/antiangiogenic markers 
 Placental growth factor (PIGF) (blood and urine) 
 Soluble fms-like tyrosine kinase one (sFlt1) 
 Soluble endoglin (sEng) 
 Vascular endothelial growth factor (VEGF) 
 Transforming Growth Factor-Beta 1 (TGFb1) 
Inflammatory markers 
 Tumour Necrosis Factor alpha (TNF α) 
 C-reactive protein (CRP) 
 Interleukin-6, -10 and -19 
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 Interferon (IFN) gamma 
 P-selectin 
 Pentraxin 
Markers of lipid metabolism and oxidative stress  
 Serum malondialdehyde (MDA),  thiobarbituric acid-reactive substances (TBARS), 
superoxide dismutase (SOD) 
 Hypertriglyceridaemia 
 Hyperlipidaemia 
Cardiac markers 
 B-type natriuretic peptides (BNP)  
Markers of renal dysfunction  
 Urinary protein to creatinine ratio (PCR)  
 Urinary calcium excretion, urinary calcium to creatinine ratio 
 Urinary proteinuria (24-hour/spot tests for total proteinuria, albuminuria, 
microalbuminuria, albumin to creatinine ratio, kallikrein, SDS-PAGE proteins) 
Prothrombotic markers 
 Factor V Leiden gene mutation 
 Prothrombin gene mutation (PGM)  
 Anticardiolipin Antibodies (ACA) 
 Antiphospholipid antibodies (APLA) 
 D-dimer 
Markers of fetoplacental unit endocrine dysfunction 
 Human chorionic gonadotrophin (HCG) 
 Alpha-Fetoprotein (AFP) 
 Inhibin A 
 Activin A 
 Pregnancy-associated plasma protein A (PAPP-A) 
 Placental protein 13 (PP13) 
 Oestriol 
 Metallopeptidase domain 12 (ADAM12) 
 Corticotropin releasing hormone 
 Serum uric acid  
 Vitamin D 
Others 
 Fibronectin (maternal blood) 
 Vitamins and mineral levels (Vitamins C and E, copper, iron and zinc levels) 
 Free fetal DNA 
Genetic associations  
 Methyltetrahydrofolate reductase (MTHFR) polymorphisms 
 Glutathione S transferase polymorphisms 
 Endothelial nitric oxide synthase polymorphisms 
 Plasminogen activator inhibitor 1 (PAI-1) polymorphism 
 VEGF polymorphisms  
 TGFb1 polymorphisms  
 IL-10 polymorphisms  
 TNF alpha polymorphisms  
 HLA-G 14bp I/D polymorphisms  
 AGT II receptor polymorphisms  
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 ACE I/D polymorphisms  
 AGT polymorphisms  
 Prothrombin gene polymorphisms 
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le Table 2a. Predictive ability of maternal characteristics for pre to eclampsia  Author Year  No. of primary studies  No. of databases searched No. of women Risk factors evaluated Reported measure of test performance Review pooled results (95% confidence intervals) Outcome reported  
Maternal characteristics (clinical assessment) 
Cnossen 2007 36 4 1699073 BMI or obesity  Sensitivity and 
Specificity 
BMI >25 Sn 47% (33 to 61) Sp 
73% (64 to 83%)  
All PE 
BMI >35 Sn 21% (12 to 31) Sp 
92% (89 to 95)  
O'Brien 2003 13 2 1390226 RR 0.54% (0.27 to 0.8) increase per 1 
kg/m
2
 increase in BMI  
All PE 
Wang 2013* 29 N/A 1980761 RR Overweight RR 1.58 (1.44 to 1.72)  All PE 
Obese RR 2.68 (2.39 to 3.01)  
Severely obese RR 3.12 (2.24 to 
4.36)  
Salihu 2012 14 2 774366 Narrative    All PE 
Poorolajal 2016 23 4 1387599 OR BMI 25 to 30 OR 1.73 (1.59 to 
1.87) 
All PE 
BMI> 30 OR 3.15 (2.96 to 3.35) 
Weissgerber 
2016 
12 3 1103 Flow mediated 
dilation  
SMD   -0.78 ( -1.19 to -0.37) All PE  
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le Alpoim 2013* 2 4 1875 ABO blood group status OR AB group OR 2.42 (1.63 to 3.58) Early-onset PE 
A group OR 0.86 (0.69-1.06) 
B group OR 1.1 (0.67-1.8)  
O group OR 0.89 (0.71-1.11)  
Franchini 2016 9 2 697285 OR O group OR 0.77 (0.67 to 0.88) All PE  
AB group OR 1.94 (1.2 to 3.13) 
A group OR 1.78 (1.04 to 3.07) 
Conde Agudelo 
2008 
5 7 8811336 Maternal 
infections (UTI, 
periodontal 
disease, HIV, 
malaria, 
Hepatitis)  
OR UTI OR 1.57 (1.45 to 1.7) All PE 
Periodontal disease OR 1.76 (1.43 
to 2.18)  
Chlamydia pneumoniae, H. pylori, 
CMV, HIV, malaria, HSV, BV, 
mycoplasma hominis: not 
associated 
Rustveld 2008 16 3 20586 OR Any infection OR 2.08 (1.63 to 
2.65) 
All PE 
Basaran 2016 6 1 47599 Chorionic villus 
sampling  
OR 0.83 (0.42 to 1.67) All PE  
Sgolastra 
2013* 
15 8 5023 Periodontal 
disease 
OR 2.17 (1.38 to 3.41) All PE 
Kunnen 2010* 15 3 Not specified Narrative    Early-onset 
PE 
Wei 2013 15 2 9192 OR 2.79 (2.01 to 3.01) All PE  
Ide 2013 5 4 5024 OR 1.61 (1.36 to 1.92) All PE 
Huang 2014 11 2 3916 OR 3.69 (2.58 to 5.27) All PE 
Huang 2016 11 2 11566 Hepatitis B  OR 0.77 (0.65 to 0.90) All PE 
Calvert 2013 9 4 14971 HIV OR 1.04 (0.60 to 1.79) All PE 
Adams 2016 13 4 21200 Narrative   All PE 
Browne 2015 16 3 8817384 OR 1.01 (0.87 to 1.18) All PE 
Zhang 2013 13 5 668005 Mental stress OR 1.49 (1.27 to 1.74) All PE 
Yu 2016 25 3 Not specified Polycystic 
ovarian 
syndrome 
OR 2.79 (2.29 to 3.38) All PE  
Qin 2013 15 3 1198662 OR 2.17 (1.91 to 2.46)  All PE 
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le Pedersen 2014 4 (PM2.5) 2 127798 (PM2.5) Ambient air pollution OR PM2.5 OR 1.31 (1.14 to 1.5)  All PE 4 (NO2) 120042 (NO2) NO2 OR 1.07 (1.02 to 1.13)  
3 (NOx) 170694 (NOx) NOx OR 1.05 (0.98 to 1.13) 
3 (PM10) 50109 (PM10) PM10 OR 1.03 (0.91, 1.17) 
3 (CO) 95853 (CO) CO OR 0.95 (0.86 to 1.05) 
3 (Traffic)  NA (traffic)  Traffic OR 1.03 (1.01 to 1.06) 
3 (O3)  115891 (O3) O3 OR 1.09 (0.98 to 1.21)  
Hu 2014 6 5 282117 OR NO2 OR 1.1 per 10 ppb (1.03 to 
1.17) 
All PE 
PM10 OR 0.98 per 10 ppb (0.91 to 
1.05) 
PM2.5 OR 1.1 (0.96 to 1.26) 
Tersigni 2014 2 2 9436 Celiac disease OR 1.41 (0.73 to 2.71)  All PE  
Wei 2015 17 2 1800000 Cigarette 
smoking 
RR 0.67 (0.6 to 0.75) All PE  
Cnossen 2008 34 4 60599 Blood pressure AUC MAP 0.76 (0.70 to 0.82)  All PE 
sBP 0.68 (0.64 to 0.72) 
dBP 0.66 (0.59 to 0.72) 
Wolf 2014* 11 2 170679 Leisure time 
physical activity  
Narrative    All PE 
Aune 2014 15 3 185121 RR 0.65 (0.47 to 0.89) All PE 
Gonzalez-
Comadran 
2014 
7 2 10898 Donor 
insemination  
OR 1.63 (1.36 to 1.95) All PE  
Blazquez 2016 11 3 26302 Donor oocyte 
use  
OR 3.05 (2.48-3.74)  All PE 
Masoudian 
2016 
4 4 16553 OR 4.34 (3.1 to 6.06) All PE 
Jeve 2016 10 7 11539 OR 2.90 (1.98-4.24) All PE 
Thomopoulos 
2017 
7 2 225279 Assisted 
reproductive 
technology use 
RR Ovulation induction RR 1.48 (1.12 
to 1.96) 
All PE 
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le IVF/ICSI RR 1.65 (1.53 to 1.77) Li 2016 3 4 167680 Intra-uterine 
device use  
RR 0.74 (0.61-0.90)  All PE 
Schalekamp-
Timmermans 
2016 
11 n/a 219575 Female fetal 
gender  
OR 1.36 (1.17-1.5)  Early-onset 
PE 
Cormick 2016 2 3 26174 Inter-pregnancy 
interval  
OR <2 years 1.01 (0.95 to 1.07) All PE  
>2 years 1.1 (1.02-1.19)  
Kangatharan 
2016 
5 4 284899 OR < 6 months 0.95 (0.88 to 1.02) All PE 
Ding 2013 12 3 9962 Sleep 
disordered 
breathing  
OR 2.19 (1.71 to 2.8) All PE  
Xu 2014 5 5 977 RR 1.96 (1.34 to 2.86) All PE  
Palmer 2013* 11 2 N/A Occupational 
exposures 
Narrative    All PE 
Schoenaker 
2014 
2 38 271472 Dietary factors  WMD Kcal/day WMD 46 ( -13.8 to 
106.23) 
All PE 
Mg intake WMD -9.75 mg/day ( -
21.26 to 1.76)  
Ca intake WMD -56.32 mg/day (-
120.69 to  8.06) 
Beltran 2014 2 24 N/A Meteorological 
factors 
RR Birth in Spring v Summer RR 1.05 
(0.87 to 1.27)  
All PE 
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le Table 2b. Ability of ultrasound markers to predict pre-eclampsia  Author Year  No. of 
primary 
studies  
No. of 
databases 
searched 
No. of 
women 
Risk factors evaluated Reported 
measure of test 
performance 
Review pooled results (95% 
confidence intervals) 
Outcome 
reported  
Velauthar 2014* 18 3 55974 First trimester uterine 
artery doppler   
 
Sensitivity and 
Specificity  
Sensitivity 47.8% (39 to 56.8%) 
Specificity 92.1% (88.6 to 94.6%) 
Early-onset 
PE 
Sensitivity 26.4% (22.5 to 30.8%) 
Specificity 93.4% (90.4 to 95.5%) 
All PE 
Cnossen 2008  3 4 4966 Sensitivity and 
Specificity  
PI: Sens 25% (20-31) Spec 95% (95-
96%)  
All PE 
Cnossen 2008  
  
7 4 38230 Second trimester uterine 
artery doppler 
 
Sensitivity and 
Specificity  
PI: Sens 42% (25-58%)  
Spec 91% (86-96%),  
All PE 
17 4 36969 Sensitivity and 
Specificity  
Bilateral notching: Sens 43% (26-60%), 
Spec 93% (90-97%)  
All PE 
Eastwood 2017 3 4 1865 Placental vascularisation 
indices in first trimester  
MD VI: MD  -2.93 ( -5.84 to  -0.01) All PE 
FI: MD  -2.83 (3.97 to  -1.69)  
VFI: MD -0.93 (-1.6 to  -0.25)  
Xu 2016 3 3 65226 Single fetal umbilical artery  OR 0.820 (0.56 to 1.21) All PE  
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Author Year  
No. of 
primary 
studies  
No. of 
databases 
searched 
No. of 
women 
Risk factors 
evaluated 
Reported 
measure of test 
performance 
Review pooled results (95% confidence 
intervals) 
Outcome 
reported  
Angiogenic and antiogenic markers 
Widmer 2007 10 5 1173 
sFlt-1 
Narrative    
Early-onset 
PE 
Kleinrouweler 
2012 
19 2 5337 OR 6.6 (3.1 to 13.7)  
Early-onset 
PE 
Allen 2014 
 
4 
3 
 
1045 OR 1.3 (1.02 to 1.65) All PE 
3 569 OR 1.2 (0.33 to 4.41) 
Early-onset 
PE 
Widmer 2007 14 5 2045 
PIGF 
 
Narrative   
Early-onset 
PE 
Kleinrouweler 
2012 
15 2 10612 OR 9.0 (5.6 to 14.5)  All PE 
Allen 2014 
 
4 
 
3 
 
987 OR 1.94 (0.81 to 4.67)  All PE 
1590 OR 3.41 (1.61 to 7.24)  
Early-onset 
PE 
Wu 2015 
8 
4 
 
Not 
specified 
Sensitivity and 
specificity  
SN 65% (63-67%), SP 89% (89-89%)  All PE  
3 
Not 
specified 
Sensitivity and 
specificity  
SN 37% (27-48%) SP 79% (78-81%)  
Early-onset 
PE  
Zhong 2015 
 
2 
4 
 
8424 
  
LR 
LR+ 4.01 (3.74 to 4.28), LR- 0.67 (0.64 to 
0.69)  
All PE  
6 LR 
LR+ 6.05 (5.55 to 6.55), LR- 0.48 (0.43 to 
0.52)  
Early-onset 
PE  
Kleinrouweler 
2012 
4 2 2143 
sEng 
OR 4.2 (2.4 to 7.2)  All PE  
Allen 2014 2 3 854 OR 1.23 (0.79 to 1.94) All PE  
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Kleinrouweler 
2012*  
3 2  265 VEGF SMD -1.25 ( -2.73 to -0.23)  All PE 
Markers of fetal placental unit function  
Schneuer 
2012* 
4 3 6161 
PP13  
Sensitivity  
All PE: 24% for 5% FPR Early to 
onset PE Early PE: 45% for 5% FPR 
Allen 2014 
4 3 3948 OR 4.42 (2.86 to 6.84) All PE 
3 3 3984 OR 7.51 (2.5 TO 22.53)  
Early-onset 
PE 
Wu 2015 9 4 n/s 
Sensitivity and 
specificity  
All PE SN 37% (33-41%) SP 89% (89-89%)  
All PE  Early PE SN 59% (48-69%) SP 92% (91-
93%) 
Zhong 2015 6 3 60786 LR 
Early PE LR+ 4.2 (3.69 to 4.71) LR- 0.6 (0.53 
to 0.66)  
All PE  
All PE LR+ 2.69 (2.05 to 3.32) LR- 0.6 (0.53 
to 0.66)  
Morris 2017 8 4 132076 
PAPP-A 
OR <5
th
 centile OR 1.94 (1.63 to 2.3) All PE  
Allen 2014 
12 3 56695 OR 2.05 (1.62 to 2.59)  All PE 
5 3 9713 OR 4.84 (2.49 to 9.41)  
Early-onset 
PE 
Wu 2015 14 4 n/s 
Sensitivity and 
specificity  
All PE SN 30% (29-32%) SP 92% (92-92%)  
All and 
early PE 
Early PE SN 26% (19-34%) SP 90% (89-
90%) 
Late PE SN 19% (14024%) SP 89% (89-
90%)  
Zhong 2015 16 3 385634 LR 
Early LR+ 2.98 (2.55 to 3.41) LR- 0.7 (0.65 to 
0.74)  Early and 
late PE  Late LR+ 1.58 (0.86 to 2.31), LR- 0.87 (0.74 
to 1.00) 
Wu 2015 14 4 n/s Inhibin A 
Sensitivity and 
specificity  
SN 32% (25-39%) SP 90% (89-91%)  All PE  
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bHCG 
SMD MoMs 2.48 (0.81 to 4.15) All PE  
Zhong 2015 6 4 n/s LR 
Early PE LR+ 1.5 (0.92 to 2.08) LR- 0.95 (0.9 
to 1.0)  
All PE  
Late PE LR+ 1.41 (0.81 to 2.46) LR-  0.95 
(0.88 to 1.03) 
Allen 2014 4 3 11651 bHCG OR 1.09 (0.86 to 1.39) All PE 
Wu 2015 3 4 n/s ADAM-12 
Sensitivity and 
specificity  
SN 26% (21-32%) SP 84% (82-86%)  All PE  
Cnossen 
2006 
5 4 572 Uric acid Narrative   All PE 
Tabesh 
2013* 
8 6 2485 
Vitamin D 
OR Deficiency 2.78 (1.45 to 5.33)  All PE 
Christesen 
2012 
10 3 28726 Narrative   All PE 
Hypponen 
2013 
6 3 6864 OR Sufficiency OR 0.52 (0.3 to 0.89) All PE 
Aghajafari 
2013 
9 5 3191 OR 1.79 (1.25 to 2.58) All PE 
Harvey 2014 11 21 26856 OR 
Sufficiency OR 0.78 (0.59 to 1.05) Deficiency 
OR 0.75 (0.48 to 1.19) 
All PE 
Inflammatory and immune markers  
Rebelo 2013* 23 3 4265 CRP WMD 2.3 mg/L (1.27 to 3.34) All PE 
Lau 2013* 41 4 1940 
IL6 and IL10 
MD 
IL-6 7.96 pg/mL (2.65 to 13.28) 
All PE 
IL -10 5.54 pg/mL (0.69 to 10.38) 
Xie 2011 43 2 
Not 
specified 
WMD 
IL-6 OR 1.23 (0.93 to 1.61) WMD 6.58 (5.49 
to 7.67)  
All PE  
IL-10 OR 1.07 (0.75 to 1.52) WMD 19.3 (8.42 
to 30.17) 
Lau 2013* 41 4 1940 
TNF alpha 
MD 8.11 pg/mL (5.87 to 10.34) All PE  
Xie 2011   2 
Not 
specified 
WMD 19.63 pg/ml (18.54-20.72) All PE  
Yang 2014 
(AJRI) 
16 3 2230 
IL-18 and IFN 
gamma  
OR 
IL -18 0.07 (-0.40 to 0.53) 
All PE  
IFN-gamma 0.93 (0.07 to 1.79) 
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Gupta 2009* 
  
  
  
  
26 
  
  
  
  
4 
  
  
  
  
1767 
  
  
  
  
Lipid peroxidation  
  
  
  
  
SMD 
  
  
  
  
Malondialdehyde: 1.21 nmol/mL (0.76 to 
1.66) 
All PE 
  
  
  
  
Thiobarbituric acid-reactive substances: 1.62 
(0.27 to 2.96) 
Vitamin E -1.12 (-1.77 to -0.48)  
Vitamin C -0.53 (-1.03 to -0.02)  
Erythrocyte superoxide dismutase -2.37 (-
4.76 to 0.03)  
Gallos 2013 29 7 5867 Hypertriglyceridaemia MD (mmol/L)  0.78 (0.6 to 0.96)  All PE  
Spracklen 
2014 
74 2 N/S Hyperlipidaemia WMD (mg/dL) 
Total cholesterol 12.49 (3.44 to 21.54)  
All PE  
HDL-C  -0.48 (-3.31 – 2.34)  
LDL-C 3.89 (-0.19 to 7.97)  
Triglycerides 25.08 (14.39 to 35.77)  
Cardiac and renal markers  
Afshani 2012 12 3 N/S BNP Narrative   All PE 
Lei 2016 6 3 480 
AGT II recepter auto 
antibodies  
OR 32.84 (17.19 to 62.74) All PE 
Thrombotic markers  
Dudding 
2008 
6 2 6755 
Factor V Leiden 
OR 1.49 (1.13 to 1.96)  All PE 
Kosmas 
2003 
18 2 4502 OR (Vv or vv): 2.25 (1.5 to 3.38)  All PE  
Rodger 
2010* 
10 2 21833 OR 1.23 (0.89 to 1.70) All PE 
Wang 2014 23 2 7167 OR 1.6 (1.28 to 2.0)  All PE 
do Prado 
2010* 
12 3 8475 
Antiphospholipid 
antibodies  
OR ACA 2.86 (1.37 to 5.98) All PE 
Abou Nassar 
2011* 
28 3 22300 OR 
LA 2.34 (1.18 to 4.64)  
All PE ACA 1.52 (1.05 to 2.2)  
Anti B2GP1 19.14 (6.34 to 57.77) 
Other tests 
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le Fan 2016 12 2 905 Serum copper levels SMD 0.69 (0.54 to 0.84)  All PE  Song 2015 26 7 2468 Serum iron SMD 1.27 (0.76-1.78)  All PE  Zhu 2016 13 2 1013 Serum zinc  SMD -0.61 (-0.74 to - 0.48)  All PE  
Leeflang 
2007 
5 4 573 FFN Narrative   All PE 
Contro 2016 9 2 1646 
cfFDNA 
DR 
68.8% (57.6 to 77.3) for 10% FPR (17-28 
weeks)  
All PE 
Martin 2014 13 2 N/S Narrative   All PE  
Combinations of markers and models 
Zhu 2015 15 3 N/S 
Combination of 
uterine artery PI, 
biomarkers and 
maternal 
characteristics 
Sensitivity alone 
Any PE 
All, early 
and late 
onset PE   
All biomarkers 0.584 (0.561 to 0.608)  
PI+activin A 0.693 (0.592 to 0.779)  
PI+inhibin A 0.68 (0.59 to 0.757) 
PI+PAPP-A 0.566 (0.401 to 0.717)  
PI+PP13 0.69 (0.475 to 0.846)  
PI+PlGF 0.88 (0.64 to 0.906) 
Early PE  
All biomarkers 0.83 (0.794 to 0.861)  
PI+MAP 0.894 (0.852 to 0.925)  
PI+PAPP-A 0.729 (0.641 to  0.801)  
PI+PLGF 0.878 (0.784 to 0.934)  
PI+PP13 0.774 (0.65 to 0.863)  
Late PE  
All biomarkers 0.585 (0.525 to 0.642)  
PI+MAP 0.570 (0.503 to 0.634)  
PI+PLGF 0.275 (0.047 to 0.746)  
PI+PP13 0.536 (0.178 to 0.861)  
PI+PAPP-A (1 study only)  
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le 0.7 (0.55 to 0.816)  Al Rubaie 2016 29 3 27958 First trimester predictive models Narrative   All PE  
Hui 2012* 8 3 115290 
Combinations of 
serum markers used 
in first trimester 
anomaly screening  
LR 
AFP+hCG >2.5 MoM LR+ 5.68 (0.73 to 
43.97) LR- 0.99 (0.98 to 1.01)  
All PE 
Kleinrouweler 
2013* 
8 2 6708 
Second trimester 
uterine artery Doppler 
+ other tests IPD 
AUC 
sBP+BMI+mean PI+bilateral notching AUC 
0.85 (0.67 to 1.0)  
Early to 
onset PE sBP+BMI AUC 0.65 (0.45 to 0.84)  
mean PI+bilateral notching AUC 0.75 (0.56 to 
0.95)  
Giguere 
2011* 
37 2   71 different markers Narrative   
Early to 
onset PE 
Kuc 2011 35 4 138571 
Multiple serum and 
ultrasound markers 
and maternal 
characteristics  
Narrative   All PE  
Multiple tests or markers assessed in single review  
Duckitt 2005 52 2 N/s 
Multiple clinical 
features 
Narrative    All PE 
Bartsch 2016 2 92 25356688 
Multiple maternal 
clinical features  
RR 
Previous IUGR 1.4 (0.6 to 3.0) 
All PE 
SLE 2.5 (1.0 to 6.3)  
Nulliparity 2.1 (1.9 to 2.4)  
Maternal age >35 1.2 (1.1 to 1.3) 
Maternal age >40 1.5 (1.2 to 2.0) 
Prior stillbirth 2.4 (1.7 to 3.4)  
CKD 2.9 (2.6 to 3.1)  
Multiple preg. 2.9 (2.6 to 3.1)  
Prior abruption 2.0 (1.4 to 2.7) 
Diabetes 3.7 (3.1 to  4.3)  
Prior PE 8.4 (7.1 to 9.9) 
Chronic HTN 5.1 (4.0 to 6.5)  
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le Antiphospholipid syndrome 2.8 (1.8 to 4.3)  ART use 1.8 (1.6 to 2.1) BMI >25 2.1 (2.0 to 2.2)  
BMI >30 2.8 (2.6 to 3.1)  
Morris 2008 44 4 169637 
AFP, hCG, estriol, 
PAPP-A, inhibin A, 
activin A 
LR 
AFP LR+ 2.36 (1.46 to 3.83) LR- 0.96 (0.95 
to 0.98)  
All PE 
hCG LR+ 2.45 (1.57 to 3.84) LR- 0.89 (0.83 
to 0.96)  
Estriol LR+ 1.5 (1.02 to 2.19) LR- 0.99 (0.97 
to 1.00)  
PAPP- A <5
th
 centile LR+ 2.1 (1.57 to 2.81) 
LR- 0.95 (0.93 to 0.98)  
Inhibin A LR+ 19.52 (8.33 to 45.79) LR to  
0.3 (0.13 to 0.68)  
Zhong 2015 6 4 n/s 
PLGF, PAPP-A, 
hCG, PP13 
LR 
PLGF: LR+ 4.01 (3.74 to 4.28) 
All PE  
PAPP-A: Early PE LR+ 2.98 (2.55 to 3.41)  
Late PE 1.58 (0.86 to 2.31) 
hCG Early PE LR+ 1.5 (0.92 to 2.08)  
Late PE LR+ 1.41 (0.81 to 2.46) 
PP13: Early PE LR 4.2 (3.69 to 4.71)  
All PE: LR+ 2.69 (2.05 to 3.32)  
  
Conde-
Agudelo 
2004  
43 4 42261 
Systematic review of 
all screening tests 
LR 
Low risk RI LR+ 4.2 (3.6 to 5.1) LR – 0.6 (0.5 
to 0.7)                          
All PE 
Bilateral notching LR+ 6.6 (5.8 to 7.4) LR to  
0.8 (0.7 to 0.8)                   
hCG >2.0 MoM LR+ 2.2 (1.7 to 2.9) LR to  
0.8 (0.8 to 0.9)                    
Urinary Kallikrein LR+ 4.6 (3.4 to 6.1) LR to  
0.3 (0.2 to 0.6)               
ACA LR+ 6.7 (4.2 to 10.9) LR to  0.8 to 0.9)      
Meads 2008 265 3 
not 
specified 
Systematic review of 
27 screening tests 
Sensitivity and 
specificity  
Bilateral notching: Sn 48% (34 to 62%) Sp 
92% (87 to 95%)     All PE  
BMI> 34 Sn 18 (15 to 21) Sp 93 (87 to 97) 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
Kallikreinuria Sn 83% (52 to 98) Sp 98% (98 
to 100)                            
Cellular fibronectin Sn 50% (30 to 70) Sp 
96% (94 to 98) 
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Author 
Year  
No. of 
primary 
studies  
No. of 
databases 
searched 
No. of 
women 
Genetic factor 
evaluated 
Reported 
measure of test 
performance 
Review pooled results 
(95% confidence intervals) 
Venice 
criteria   
Outcome 
reported  
Song 2013 10 2 2068 VEGF OR 1.35 (1.11 to 1.65)  
BBB 
Any onset PE  
Cheng 
2013 
8 3 1838 
  
OR  
+936C/T OR 1.52 (1.08 to 
2.12) 
BBA Any onset PE  
  
-634G/C OR 1.24 (1.03 to 
1.5)  
  
-2578C/A OR 0.98 (0.82 to 
1.16)  
  -1154G/A OR 1.30 (0.94 to 
1.78) 
Li 2014  4 3 1084 TGFb1 OR OR 0.73 (0.56 to 0.95)  
BAB 
Any onset PE  
Yang 2014 
(JCMM) 
12 3 5493 
IL-10  
polymorphisms 
OR 
 -819c/T OR 1.28 (1.08 to 
1.5) 
ACA Any onset PE  
 -592c/A OR 1.28 (1.03 to 
1.59) 
 -1082A/G 0.93 (0.77 to 
1.13) 
Zhang 
2016 
13 6 n/s OR 
TvC OR 0.79 (0.58 to 1.07)  
ACB Any onset PE  
GvA OR 0.91 (0.75 to 1.11)  
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Lee 2014 2 11 3805 OR 
1082 G/A OR 0.89 (0.73 to 
1.09)  
ACB Any onset PE 
-819 C/T OR 1.3 (1.01 to 
1.66)  
-592 C/A OR 1.22 (0.97 to 
1.53)  
Bombell 
2008 
16 3 2374 TNF alpha  OR 1.02 (0.86 to 1.2)  
ABB 
Any onset PE 
Pabalan 
2015 
11 3 1916 
HLA-G 14bp I/D 
polymorphism 
OR 
Homozygous OR 1.28 (0.93 
to 1.75) 
BAB 
Any onset PE  
Anvar 2011 5 11 1217 
Glutathione S 
transferase 
polymorphisms 
OR 
GSTM1 OR 0.99 (0.78 to 
1.25) 
CCC Any onset PE  
GSTT1 OR 0.85 (0.66 to 
1.10) 
Dai 2013* 29 5 3228 
eNOS 
polymorphisms 
OR 
 -786 T>C OR 1.17 (1.02 to 
1.35)  
ABB Any onset PE 
4b/a OR 1.46 (1.01 to 2.1) ;  
Qi 2013* 33 3 10671 OR 
G894T OR 1.43 (1.13 to 
1.82) 
ACA 
Any onset PE 
Shaik 2011 16 2 4485 OR 0.96 (0.75 to 1.23) 
ACB 
Any onset PE  
Chen 
2012*  
18 3 N/A OR 
G849T: G allele OR 0.56 
(0.33 to 0.97), T allele OR 
1.17 (1.01 to 1.36) 
ACB 
Any onset PE 
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le Zeng 2016 17 5 4729 OR G894T: 1.46 (1.21 to 1.77)  ABA Any onset PE  T-786C: 1.3 (1.07 to 1.58) 
Yu 2006 12 2 3513 
eNOS 
polymorphisms 
OR 
Asp298 allele homozygous 
1.12 (0.84-1.49) 
ABA 
Any onste PE 
Morgan 
2013* 
12 3 5003 
PAI1 polymorphism 
OR 1.28 (1.09 to 1.50)  
AAB 
Any onset PE 
Zhao 
2012( Mol 
Hum Rep) 
11 3 3088 OR 1.36 (1.13 to 1.64)  
BAB 
Any onset PE  
Xia 2012* 36 4 9203 
MTHFR gene 
C677T 
polymorphism 
OR 1.25 (1.02 to 1.54) 
ABB 
Any onset PE 
Li 2014* 49 4 18009 OR 
White OR 1.14 (1.03 to 1.25)  
AAA Any onset PE 
Asian OR 1.41 (1.11 to 1.79)  
Wang 
2013*  
51 6 17749 OR 1.28 (1.07 to 1.53)  
ABB 
Any onset PE 
Wu 2015 45 4 88628 OR  1.157 (1.057 to 1.266) 
ACB 
Any onset PE  
Kosmas 
2004 
23 2 6213 OR 1.21 (1.01 to 1.44) 
ACB 
Any onset PE 
Zhang 
2016 
58 6 36438 OR 1.17 (1.05 to 1.31) 
ACB 
Any onset PE  
Zhao 2012 
(JMFNM) 
8 4 3990 
AGT II receptor 
polymorphisms  
OR 
+1166A>C OR 1.19 (0.96 to 
1.47) ABB 
Any onset PE 
Staines-
Urias 2012 
192 3 
Not 
specified 
AGTR1 rs186 OR 1.22 (0.96 to 1.56)  AAA Any onset PE 
Shaik 2011 17 2 3778 
ACE I/D 
polymorphism 
OR 0.987 (0.698 to 1.395) ACB Any onset PE  
Zhong 
2012 
11 5 1749 OR D allele: 1.93 (1.19 to 3.12) 
BCB 
Any onset PE 
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Zhu 2012* 23 6 3551 OR D allele: 1.31 (1.09 to 1.57) 
ACB 
Any onset PE  
Staines-
Urias 2012 
192 3 
Not 
specified 
ACE rs4646994 OR 1.17 (0.99 to 1.4)  
AAA 
Any onset PE 
Ni 2012* 22 4 7534 
AGT polymorphisms 
OR 1.33 (1.09 to 1.61) 
AAB 
Any onset PE 
Lin 2012 31 5 8669 OR 1.61 (1.22 to 2.14) 
ABA 
Any onset PE  
Zafarmand 
2008 
17 3 5275 OR 1.62 (1.12 to 2.33) ABA Any onset PE 
Staines-
Urias 2012 
192 3 
Not 
specified 
AGT rs699 OR 1.26 (1.00 to 1.59)  AAA Any onset PE 
Rodger 
2010 
6 2 14254 
Prothrombin gene 
polymorphisms 
OR 1.25 (0.79 to 1.99) BAB Any onset PE  
Wang 2014 16 2 5558 OR 
G20210A OR 181 (1.25 to 
2.63) 
AAB 
Any onset PE  
 
OR (Odds Ratio), RR (Relative risk), SMD (summary mean difference), WMD (weighted mean difference), AUC (area under curve), LR (likelihood ratio), Sn 
(sensitivity), Sp (Specificity)  
 
BMI (body mass index), UTI (urinary tract infection), HIV (human immunodeficiency virus), CMV (cytomegalovirus), HSV to 2 (herpes simplex virus), PM2.5, 
(Particulate matter) CRP (C reactive protein), PI (pulsatility index), RI (resistance index), ADAM to 12 (a disintegrin and metalloprotease), TNF alpha (tumour 
necrosis factor alpha), IL 6,10, 18 (Interleukin 6, 10, 18) PAI to 1 (Plasminogen activator inhibitor), PP13 (placental protein 3), PAPP to A (pregnancy associated 
plasma protein A), hCG (human chorionic gonadotrophin), FFN (fetal fibronectin), cffDNA (cell free fetal DNA), eNOS (endothelial nitric oxide synthase), 
AGT(Angiontensin), UtA (uterine artery), PLGF (Placental growth factor), MAP (mean arterial pressure), SBP (systolic blood pressure), sEng (soluble endoglin), 
VEGF (vascular endothelial growth factor), ART (assisted reproductive technologies), TGFb (transforming growth factor beta 1), IFN (interferon), BNP (b naturietic 
peptide), ACE (angiotensin converting enzyme), HLA (human leukocyte antigen), sFlt to 1 (soluble fms to like tyrosine kinase 1), MTHFR (methyltetrahydrofolate 
receptor)  
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Potentially relevant citations identified by searching 
MEDLINE (1946–March 2017), EMBASE (1947–March 
2017), The Cochrane Library (since inception) including 
The Cochrane Database of Systematic Reviews 
(CDSR), Database of Abstracts of Reviews of Effects 
(DARE) and The Cochrane Central Register of 
Controlled Trials (CENTRAL) and by hand-searching 
reference lists (n =2444 ) 
Citations retrieved for detailed evaluation of full 
manuscript (n = 174) 
Citations excluded  (n = 2270) 
• Not relevant 
• Therapeutic 
• Prevention 
• Not systematic reviews 
• Duplicates 
Full text articles excluded (n=42) 
• Practice guideline (n=1) 
• Did not fulfil the inclusion criteria (n=35) 
• Separate analysis for pre-eclampsia was not 
performed ; outcomes grouped together (n=12) 
Studies included in the systematic review (n = 126) 
Maternal 
characteristics* 
(n = 48) 
Biochemical 
markers* 
(n = 39) 
Combinations 
and models  
(n = 6) 
Figure 1 Flow chart illustrating identification of studies included in this systematic review.  *some studies reported 
on markers in more than one category  
Ultrasound 
markers* 
(n = 6) 
Genetic 
association* 
(n = 32) 
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Figure 2a - AMSTAR assessment of included studies  
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Figure 2b - QUIPS assessment of included studies  This article is protected by copyright. All rights reserved.
Accepted Article
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